Table 1. Study and patient's characteristics.

Study	N. centers/country	Treatment period; years	N. evaluable patients*	Metastatic RMS; %	Age; median years (range)	Gender; % males
Non-randomized controlled studies
Carli 1999/2004 [36], [107]	5/Europe	HSCT 1991 to 1995 vs. (historical) control 1989 to 1991	52 vs. 44	100 vs. 100	(0 to 18)	–
Hosoi 2007 [37]	63/Japan	1991 to 2002	22 vs. 20	100 vs. 100	(0 to 20)	–
Klingebiel 2008 [38]	50†/Europe	1995 to 2003	34 vs. 40	100 vs. 100	(under 22)	–
Single-arm studies with aggregate data
Bisogno 2009 [39]	1/Italy	–	70‡	100	(0 to 20)	47
Yamada 2007 [40]	1/Japan	–	7	86 (6/7)	(15 to 32)	29

– information not reported in the publication or not applicable.

*for non-randomized controlled studies: HSCT vs. control.

^†Klingebiel 2008: 295 patients were registered at 88 centers; 96 patients from 50 centers were analyzed in the study.

^‡Bisogno 2009: 11% patients (8 of 70 patients) without HSCT included.

Abbreviation. HSCT: hematopoietic stem cell transplantation; RMS: rhabdomyosarcoma.